Swiss National Bank Trims Stake in DexCom by 4.8%

Institutional investor reduces position in medical device company

Mar. 12, 2026 at 11:54am

Got story updates? Submit your updates here. ›

Swiss National Bank, a major institutional investor, has reduced its stake in DexCom, Inc. (NASDAQ:DXCM) by 4.8% during the third quarter. The bank now owns approximately 1.13 million shares of the medical device company, worth around $76 million.

Why it matters

DexCom is a leading manufacturer of continuous glucose monitoring (CGM) systems, which are important tools for diabetes management. Changes in institutional ownership can provide insights into investor sentiment and the stock's performance outlook.

The details

According to a recent 13F filing, Swiss National Bank sold 56,600 shares of DexCom during the third quarter, reducing its total position to 1,130,300 shares. The bank now owns approximately 0.29% of DexCom's outstanding shares.

  • Swiss National Bank made the share sale during the third quarter of the year.

The players

Swiss National Bank

A major institutional investor and the central bank of Switzerland.

DexCom, Inc.

An American medical device company that develops and manufactures continuous glucose monitoring (CGM) systems for people with diabetes.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Swiss National Bank's DexCom stake, while relatively small, could signal a shift in investor sentiment towards the medical device company. However, DexCom remains a well-regarded player in the CGM market, and the stock continues to garner positive analyst coverage.